Biologic and oral DMARDs approved for the treatment of patients with rheumatoid arthritis
| Agent | Mechanism of action | Location | Regimen |
|---|---|---|---|
| Etanercept | TNFi | USA and Europe | Monotherapy |
| Adalimumab | TNFi | USA and Europe | Monotherapy |
| Infliximab | TNFi | USA and Europe | In combination with MTX |
| Certolizumab pegol | TNFi | USA and Europe | Monotherapy |
| Golimumab | TNFi | USA and Europe | In combination with MTX |
| Tocilizumab | IL-6 inhibitor | USA and Europe | Monotherapy |
| Anakinra | IL-1 receptor inhibitor | USA | Monotherapy |
| Abatacept | Inhibitor of T-cell activation (costimulation modulator) | USA | Monotherapy |
| Rituximab | Anti-CD20 | USA and Europe | In combination with a DMARD |
| Tofacitinib | JAK inhibitor | USA | Monotherapy |
DMARD, disease-modifying antirheumatic drug; IL, interleukin; JAK, janus kinase; MTX, methotrexate; TNFi, tumour necrosis factor inhibitor.